Lactoferrin: Antimicrobial activity and therapeutic potential

Seminars in Fetal and Neonatal Medicine

Volumn 18, Issue 3, 2013, Pages 143-149

  Embleton, Nicholas D ^a,b   Berrington, Janet E ^a,b   McGuire, William ^c   Stewart, Chris J ^d   Cummings, Stephen P ^d  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

Lactoferrin; Late onset infection; Microbiome; Necrotising enterocolitis

Indexed keywords

LACTOFERRIN; PROBIOTIC AGENT; TALACTOFERRIN;

ADVERSE OUTCOME; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BREAST MILK; CHEMICAL STRUCTURE; HUMAN; LATE ONSET SEPSIS; MALNUTRITION; MICROBIOME; NECROTIZING ENTEROCOLITIS; NONHUMAN; NUTRITIONAL STATUS; PREMATURE LABOR; PREMATURITY; PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SUPPLEMENTATION; SURVIVAL RATE;

EID: 84892431979     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2013.02.001     Document Type: Review

References (52)

1. Berrington J.E., Hearn R., Bythell M., Wright C., Embleton N.D. Deaths in preterm infants: changing pathology over 2 decades. JPediatr 2012, 160:49-53.
2. Vergnano S., Menson E., Kennea N., et al. Neonatal infections in England: the neonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011, 96:F9-14.
3. Embleton N.D., Yates R. Probiotics and other preventative strategies for necrotising enterocolitis. Semin Fetal Neonat Med 2008, 13:35-43.
4. Berrington J.E., Stewart C., Embleton N.D., Cummings S.P. Gut microbiota in preterm infants: assessment and relevance to health and disease. Arch Dis Child Fetal Neonatal Ed 2012 Sep 25, http://dx.doi.org/10.1136/archdischild-2012-302134.
5. Manzoni P., Ranaldi M., Cattani S., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009, 302:1421-1428.
6. Stewart C.J., Marrs E.C.L., Mcgorrian S., et al. The preterm gut microbiota: changes associated with necrotizing enterocolitis and infection. Acta Paediatr 2012, 101:1121-1127.
7. Caicedo R.A., Schanler R.A., Li N., Neu J. The developing intestinal ecosystem: implications for the neonate. Pediatr Res 2005, 58:625-628.
8. Bevins C.L., Salzman N.H. The potter's wheel: the host's role in sculpting its microbiota. Cell Molec Life Sci 2011, 68:3675-3685.
9. Backhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011, 58(Suppl. 2):44-52.
10. Madan J.V., Salari R.C., Saxena D., et al. Gut microbial colonisation in premature neonates predicts neonatal sepsis. Arch Dis Child Fetal Neonatal Ed 2012, 97:F456-F462.
11. Wang Y., Hoenig J.D., Malin K., et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. Int Soc Microb Ecol J 2009, 3:944-954.
12. Björkström M.V., Hall L., Söderlund S., Håkansson E.G., Håkansson S., Domellöf M. Intestinal flora in very low-birth weight infants. Acta Paediatr 2009, 98:1762-1767.
13. LaTuga M.S., Ellis J.C., Cotton C.M., et al. Beyond bacteria: a study of the enteric microbial consortium in extremely low birth weight infants. PLoS One 2011, 6:e27858.
14. Fouhy F., Ross R.P., Fitzgerald G., Stanton C., Cotter P.D. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps. Gut Microbes 2012, 3:1-18.
15. Deshpande G.C., Rao S.C., Keil A.D., Patole S.K. Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med 2011, 9:92.
16. Montreuil J., Tonnet J., Mullet S. Préparation et propriétés de la lactosidérophiline (lactotransferrine) du lait de femme. Biochim Biophys Acta 1960, 45:413-421.
17. Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 2012, 90:252-268.
18. Ronayne De Ferrer P.A., Baroni A., Sambucetti M.E., Lopez N.E., Ceriani C. Lactoferrin levels in term and preterm milk. JAm Coll Nutr 2000, 19:370-373.
19. Mehta R., Petrova A. Biologically active breast milk proteins in association with very preterm delivery and stage of lactation. JPerinatol 2011, 31:58-62.
20. Leaf A., Dorling J., Kempley S., et al. Early or delayed enteral feeding for preterm growth restricted infants: a randomized trial. Pediatrics 2012, 129:e1260-e1268.
21. Teng C.T. Lactoferrin gene expression and regulation: an overview. Biochem Cell Biol 2002, 80:7-16.
22. Mariller C., Hardivill S., Hoedt E., Huvent I., Pina-Canseco S., Pierce A. Delta-lactoferrin, an intracellular lactoferrin isoform that acts as a transcription factor. Biochem Cell Biol 2012, 90:307-319.
23. Ward P.P., Mendoza-Meneses M., Cunningham G.A., Conneely O.M. Iron status in mice carrying a targeted disruption of lactoferrin. Molec Cell Biol 2003, 23:178-185.
24. Lönnerdal B., Jiang R., Du X. Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities. JPediatr Gastroenterol Nutr 2011, 53:606-614.
25. Venkatesh M.P., Rong L. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. JMed Microbiol 2008, 57:1113-1121.
26. Payne S.M., Finkelstein R.A. Pathogenesis and immunology of experimental gonococcal infection: role of iron in virulence. Infect Immun 1975, 12:1313-1318.
27. Gado I., Erdie J., Laszlo V. Correlation between human lactoferrin binding and colicin susceptibility in Escherichia coli. Antimicrob Agents Chemother 1991, 35:2538-2543.
28. Suzuki Y.A., Wong H., Ashida K.Y., Schryvers A.B., Lonnerdal B. The N1 domain of human lactoferrin is required for internalization by caco-2 cells and targeting to the nucleus. Biochem 2008, 47:10915-10920.
29. Van der Strate B.W.A., Harmsen M.C., Schafer P., et al. Viral load in breast milk correlates with transmission of human cytomegalovirus to preterm neonates, but lactoferrin concentrations do not. Clin Diagn Lab Immunol 2001, 8:818-821.
30. Ochoa T.J., Clearly T.G. Lactoferrin disruption of bacterial type III secretion systems. BioMetals 2004, 17:257-260.
31. Fischer R., Debbabi H., Dubarry M., Boyaka P., Tome D. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem Cell Biol 2006, 84:303-311.
32. De La Rosa G., Yang D., Tewart P., Varadhachary A., Oppenheim J.J. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. JImmunol 2008, 180:6868-6876.
33. Ishii K., Takamura N., Shinohara M., et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 2003, 25:226-233.
34. Kuhara T., Yamauchi K., Tamura Y., Okamura H. Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. JInterferon Cytokine Res 2006, 26:489-499.
35. Bullen J.J., Rogers H.J., Leigh L. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. BMJ 1972, 1:69-75.
36. Cornish J., Palmano K., Callon K.E., et al. Lactoferrin and bone; structure-activity relationships. Biochem Cell Biol 2006, 84:297-302.
37. Dial E.J., Dohrman A.J., Romero J.J., Lichtenberger L.M. Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. JPharm Pharmacol 2005, 57:93-99.
38. Selimoglu M.A., Temel L., Yildirim C., Ozyalin F., Aktas M., Karabiber H. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis. Pediatr Crit Care Med 2012, 13:452-454.
39. Paesano R., Pietropaoli M., Berlutti F., Valento P. Bovine lactoferrin in preventing preterm delivery associated with sterile inflammation. Biochem Cell Biol 2012, 90:468-475.
40. Giunta G., Giuffrida L., Mangano K., Fagone P., Cianci A. Influence of lactoferrin in preventing preterm delivery: a pilot study. Molec Med Rep 2012, 5:162-166.
41. Superti F., Ammendolia M.G., Valenti P., Seganti L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte like cell line HT-29. Med Microbiol Immunol 1997, 186:83-91.
42. Ochoa T.J., Cleary T.G. Effect of lactoferrin on enteric pathogens. Biochimie 2009, 91:30-34.
43. Ochoa T.J., Pezo A., Cruz K., Chea-Woo E., Cleary T.G. Clinical studies of lactoferrin in children. Biochem Cell Biol 2012, 90:457-467.
44. Egashira M., Takayanagi T., Moriuchi M., Moriuchi H. Does daily intake of bovine lactoferrin-containing products ameliorate rotaviral gastroenteritis?. Acta Paediatr 2007, 96:1242-1244.
45. Zavaleta N., Figueroa D., Rivera J., Sanchez J., Alfaro S., Lonnerdal B. Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea. JPediatr Gastroenterol Nutr 2007, 44:258-264.
46. Ochoa T.J., Chea-Woo E., Campos M., et al. Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children. Clin Infect Dis 2008, 46:1881-1883.
47. Williams T.J., Schneider R.P., Willcox M.P.D. The effect of protein-coated contact lenses on the adhesion and viability of gram negative bacteria. Curr Eye Res 2003, 27:227-235.
48. Valenti P., Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 2005, 62:2576-2587.
49. Schanler R.J., Lau C., Hurst N.M., Smith E.O. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. Pediatrics 2005, 116:400-406.
50. Lucas A. Long-term programming effects of early nutrition - implications for the preterm infant. JPerinatol 2005, 25(Suppl. 2):S2-S6.
51. Pan Y., Wan J., Roginski H. Effect of chemical modification on anti-microbial and anti-viral properties of milk proteins. Aust J Dairy Technol 2005, 60:149-151.
52. Lactoferrin immunoprophylaxis for very preterm infants. Arch Dis Child Fetal Neonatal Ed 2011, 98:F2-F4. Elfin Trial Investigators Group.